Every 10-Q that TScan Therapeutics, Inc. (TCRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCRX filings page.
TScan Therapeutics, Inc. reported continued operating losses and liquidity pressure for the quarter ended June 30, 2026. Collaboration and license revenue was $1.1 million, down from $3.1 million a year earlier, reflecting timing of work under its Amgen collaboration. Research and development expense decreased to $23.4 million from $32.6 million as the company reduced lab spend and headcount after prioritizing its hematologic malignancy programs. General and administrative expense declined modestly to $8.1 million.
Net loss for the quarter was $30.4 million, compared with $37.0 million in the prior-year period. As of June 30, 2026, TScan held $100.2 million in cash and cash equivalents (plus $5.0 million restricted cash) and had an accumulated deficit of $563.9 million. Management states that existing cash is expected to fund operations into the second quarter of 2027, but concludes that substantial doubt exists about the company’s ability to continue as a going concern for 12 months after the financial statements’ issuance.
The company has a $32.5 million term loan outstanding under a Silicon Valley Bank facility, bearing interest at a minimum of 7.00% and subject to a 5% final payment fee. Because TScan did not meet a specified financial milestone by June 30, 2026, interest-only payments will end on September 30, 2026 and principal amortization will accelerate, with the loan now scheduled to mature on September 1, 2028.
TScan Therapeutics, Inc. reported a net loss of $28.7 million for the quarter ended March 31, 2026, compared with $34.1 million a year earlier, as research and development spending declined.
Collaboration and license revenue from its Amgen partnership was $982,000, down from $2.2 million, reflecting timing of research activities. Research and development expenses fell to $21.9 million from $29.8 million, mainly due to lower laboratory, facility and clinical costs after prioritizing its hematologic malignancy program.
The company ended the quarter with $128.1 million in cash and cash equivalents and total cash, cash equivalents and restricted cash of $133.1 million. Management believes this will fund its current operating plan into the second half of 2027 as it advances TCR-T cell therapy candidates, including lead program TSC-101 for acute myeloid leukemia and myelodysplastic syndrome.
TScan Therapeutics reported third-quarter results, highlighting collaboration revenue and continued investment in its TCR-T pipeline. Q3 2025 collaboration and license revenue was $2.5 million, while research and development expense reached $31.7 million and general and administrative expense was $7.9 million. The company recorded a net loss of $35.7 million.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $184.5 million, and long‑term debt was $32.4 million. Year to date, revenue was $7.8 million, primarily from the Amgen collaboration.
After aligning with the FDA on a registrational path for TSC‑101, TScan prioritized its heme program, paused enrollment in its solid tumor Phase 1 trial, and implemented a workforce reduction of approximately 30% (66 roles). The company expects a one‑time charge of up to $2.3 million in Q4 2025 and now expects its cash resources to fund operations into the second half of 2027. As of November 7, 2025, shares outstanding were 52,471,405 voting common and 4,276,588 non‑voting common.
TScan Therapeutics reported results for the quarter ended June 30, 2025, reflecting continued investment in its TCR-T therapy pipeline and collaborations. Revenue for the quarter was $3.1 million ( $5.2 million for the six months), driven by research activity under the Amgen collaboration that included a $30 million upfront payment. R&D and G&A increased to $32.6 million and $9.1 million for the quarter, respectively, resulting in a quarterly net loss of $37.0 million (six-month net loss $71.1 million), or $0.28 per share for the quarter.
The company held $169.4 million in cash and cash equivalents and $48.7 million in marketable securities as of June 30, 2025 (totaling ~$218.0 million excluding restricted cash), which management says supports operations into the first quarter of 2027. Long-term debt included a SVB term loan with $32.5 million principal outstanding and an effective interest rate of 8.46%. The filing also highlights regulatory progress with multiple Phase 1 INDs and continued R&D expenditures, alongside disclosed risks and expected ongoing losses.